Jie Lin1,2,3, Julie A Bytnar1,3, Brett J Theeler4,5, Katherine A McGlynn6, Craig D Shriver1,2, Kangmin Zhu1,2,3,7. 1. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland. 2. Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 3. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland. 4. Department of Neurology, Walter Reed National Military Medical Center, Bethesda, Maryland. 5. Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 7. Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Abstract
BACKGROUND: Glioma is the most common malignant brain cancer. Accessibility to health care is an important factor affecting cancer outcomes in the US general population. The US Military Health System (MHS) provides universal health care to its beneficiaries. It is unknown whether this universal health care has translated into improved survival outcomes among MHS beneficiaries with glioma. This study compared the overall survival of patients with glioma in the MHS with the overall survival of patients with glioma in the general population. METHODS: The MHS cases were identified from the Department of Defense's Automated Central Tumor Registry (ACTUR). Glioma cases from the general population were identified from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. SEER cases were matched 2:1 to ACTUR cases by age, sex, race, histology, and diagnosis year. All cases had histologically confirmed glioma diagnosed between January 1, 1987, and December 31, 2013. A Kaplan-Meier analysis was conducted to compare survival between the ACTUR and SEER cases. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: The study included 2231 glioma cases from ACTUR and 4462 cases from SEER. ACTUR cases exhibited significantly better overall survival than SEER cases (HR, 0.74; 95% CI, 0.67-0.83). The survival advantage of the ACTUR patients was observed in most subgroups stratified by age, sex, race, diagnosis year, and histology. For glioblastoma, the survival advantage was observed in both the pre- and post-temozolomide periods. CONCLUSIONS: Universal MHS health care may have translated into improved survival outcomes in glioma. Future studies are warranted to identify factors contributing to the improved survival.
BACKGROUND: Glioma is the most common malignant brain cancer. Accessibility to health care is an important factor affecting cancer outcomes in the US general population. The US Military Health System (MHS) provides universal health care to its beneficiaries. It is unknown whether this universal health care has translated into improved survival outcomes among MHS beneficiaries with glioma. This study compared the overall survival of patients with glioma in the MHS with the overall survival of patients with glioma in the general population. METHODS: The MHS cases were identified from the Department of Defense's Automated Central Tumor Registry (ACTUR). Glioma cases from the general population were identified from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. SEER cases were matched 2:1 to ACTUR cases by age, sex, race, histology, and diagnosis year. All cases had histologically confirmed glioma diagnosed between January 1, 1987, and December 31, 2013. A Kaplan-Meier analysis was conducted to compare survival between the ACTUR and SEER cases. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: The study included 2231 glioma cases from ACTUR and 4462 cases from SEER. ACTUR cases exhibited significantly better overall survival than SEER cases (HR, 0.74; 95% CI, 0.67-0.83). The survival advantage of the ACTUR patients was observed in most subgroups stratified by age, sex, race, diagnosis year, and histology. For glioblastoma, the survival advantage was observed in both the pre- and post-temozolomide periods. CONCLUSIONS: Universal MHS health care may have translated into improved survival outcomes in glioma. Future studies are warranted to identify factors contributing to the improved survival.
Authors: Xiao-Cheng Wu; Mary Jo Lund; Gretchen G Kimmick; Lisa C Richardson; Susan A Sabatino; Vivien W Chen; Steven T Fleming; Cyllene R Morris; Bin Huang; Amy Trentham-Dietz; Joseph Lipscomb Journal: J Clin Oncol Date: 2011-12-05 Impact factor: 44.544
Authors: Carol E DeSantis; Rebecca L Siegel; Ann Goding Sauer; Kimberly D Miller; Stacey A Fedewa; Kassandra I Alcaraz; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-02-22 Impact factor: 508.702
Authors: Matthew Koshy; John L Villano; Therese A Dolecek; Andrew Howard; Usama Mahmood; Steven J Chmura; Ralph R Weichselbaum; Bridget J McCarthy Journal: J Neurooncol Date: 2011-10-09 Impact factor: 4.130
Authors: Robert Dubrow; Amy S Darefsky; Daniel I Jacobs; Lesley S Park; Michal G Rose; Maxwell S H Laurans; Joseph T King Journal: Neuro Oncol Date: 2013-09-17 Impact factor: 12.300
Authors: Arya Amini; Norman Yeh; Bernard L Jones; Edward Bedrick; Yevgeniy Vinogradskiy; Chad G Rusthoven; Ava Amini; William T Purcell; Sana D Karam; Brian D Kavanagh; Saketh R Guntupalli; Christine M Fisher Journal: Am J Clin Oncol Date: 2018-05 Impact factor: 2.339
Authors: Desmond A Brown; Benjamin T Himes; Panagiotis Kerezoudis; Yirengah M Chilinda-Salter; Sanjeet S Grewal; Joshua A Spear; Mohamad Bydon; Terry C Burns; Ian F Parney Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Erqi L Pollom; Dylann K Fujimoto; Summer S Han; Jeremy P Harris; Suzanne A Tharin; Scott G Soltys Journal: J Radiat Res Date: 2018-03-01 Impact factor: 2.724